These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 8968213)
1. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects. Dalakas MC Ann Neurol; 1995 May; 37 Suppl 1():S2-13. PubMed ID: 8968213 [TBL] [Abstract][Full Text] [Related]
2. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. van Seventer GA; Newman W; Shimizu Y; Nutman TB; Tanaka Y; Horgan KJ; Gopal TV; Ennis E; O'Sullivan D; Grey H J Exp Med; 1991 Oct; 174(4):901-13. PubMed ID: 1717633 [TBL] [Abstract][Full Text] [Related]
3. Immunopathogenesis of inflammatory myopathies. Dalakas MC Ann Neurol; 1995 May; 37 Suppl 1():S74-86. PubMed ID: 8968219 [TBL] [Abstract][Full Text] [Related]
4. Autoreactive T and B cells in nervous system diseases. Sun JB Acta Neurol Scand Suppl; 1993; 142():1-56. PubMed ID: 8382894 [TBL] [Abstract][Full Text] [Related]
5. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. van der Meché FG; van Doorn PA Ann Neurol; 1995 May; 37 Suppl 1():S14-31. PubMed ID: 8968214 [TBL] [Abstract][Full Text] [Related]
6. [Immunopathology and treatments of Guillain-Barré syndrome and of chronic inflammatory demyelinating polyneuropathy]. Radziwill AJ; Kuntzer T; Steck AJ Rev Neurol (Paris); 2002 Mar; 158(3):301-10. PubMed ID: 11976589 [TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: immune mechanism and update on current therapies. Bansil S; Cook SD; Rohowsky-Kochan C Ann Neurol; 1995 May; 37 Suppl 1():S87-101. PubMed ID: 8968220 [TBL] [Abstract][Full Text] [Related]
8. [Target antigens in neuroimmunological diseases]. Tabira T Nihon Rinsho; 1994 Nov; 52(11):2855-60. PubMed ID: 7996680 [TBL] [Abstract][Full Text] [Related]
9. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Dalakas MC Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245 [TBL] [Abstract][Full Text] [Related]
10. Costimulation with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 augments activation-induced death of antigen-specific CD4+ T lymphocytes. Damle NK; Klussman K; Leytze G; Aruffo A; Linsley PS; Ledbetter JA J Immunol; 1993 Sep; 151(5):2368-79. PubMed ID: 7689606 [TBL] [Abstract][Full Text] [Related]
11. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. Weathington NM; Blalock JE Expert Rev Vaccines; 2003 Feb; 2(1):61-73. PubMed ID: 12901598 [TBL] [Abstract][Full Text] [Related]